Imara supplements merger proxy with lawsuit update and executive compensation details

Enliven Therapeutics, Inc.

Lawsuit filed Nov 23, 2022 voluntarily dismissed Jan 19, 2023; Imara says meritless.
Pipeline chart updated: ELVN-002 advanced to Phase 1 clinical trial.
SVB Securities received $2.2M fees from Imara in past 2 years; disclosed as supplemental.
Post-merger: Kintz base salary to $550K, Collins to $465K, Hohl to $410K; bonus targets increased.
Enliven executives to receive change-in-control severance with 12-18 months salary and equity vesting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.